Alterity Therapeutics Ltd
ATHE5.290USD
+0.280+5.59%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
46.91MMarktkapitalisierung
--KGV TTM
mehr Informationen über Alterity Therapeutics Ltd Unternehmen
Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. ATH434 has been granted Orphan designation for the treatment of MSA. The Phase II clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage MSA.
Unternehmensinformationen
BörsenkürzelATHE
Name des UnternehmensAlterity Therapeutics Ltd
IPO-datumMar 28, 2000
CEODr. David A. Stamler, M.D.
Anzahl der mitarbeiter10
WertpapierartDepository Receipt
GeschäftsjahresendeMar 28
AddresseL 3 460 Bourke St
StadtMELBOURNE
BörseNASDAQ Capital Market Consolidated
LandAustralia
Postleitzahl3000
Telefon61393494906
Websitehttps://alteritytherapeutics.com/
BörsenkürzelATHE
IPO-datumMar 28, 2000
CEODr. David A. Stamler, M.D.
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Abby Macnish Niven
Ms. Abby Macnish Niven
Chief Financial Officer, Company Secretary
Chief Financial Officer, Company Secretary
--
--
Mr. Lawrence B. Gozlan
Mr. Lawrence B. Gozlan
Non-Executive Director
Non-Executive Director
--
--
Mr. Peter Ashley Marks
Mr. Peter Ashley Marks
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Brian Derek Meltzer
Mr. Brian Derek Meltzer
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Hannah Howlett
Ms. Hannah Howlett
Investor Relations
Investor Relations
--
--
Mr. Geoffrey Paul Kempler
Mr. Geoffrey Paul Kempler
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
Dr. David A. Stamler, M.D.
Dr. David A. Stamler, M.D.
Chief Executive Officer
Chief Executive Officer
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Abby Macnish Niven
Ms. Abby Macnish Niven
Chief Financial Officer, Company Secretary
Chief Financial Officer, Company Secretary
--
--
Mr. Lawrence B. Gozlan
Mr. Lawrence B. Gozlan
Non-Executive Director
Non-Executive Director
--
--
Mr. Peter Ashley Marks
Mr. Peter Ashley Marks
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Brian Derek Meltzer
Mr. Brian Derek Meltzer
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Hannah Howlett
Ms. Hannah Howlett
Investor Relations
Investor Relations
--
--
Mr. Geoffrey Paul Kempler
Mr. Geoffrey Paul Kempler
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Sun, Jul 20
Aktualisiert: Sun, Jul 20
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Point72 Asset Management, L.P.
0.86%
Morgan Stanley & Co. LLC
0.28%
Greenleaf Trust
0.11%
UBS Financial Services, Inc.
0.08%
BNP Paribas Securities Corp. North America
0.06%
Other
98.60%
Aktionäre
Aktionäre
Anteil
Point72 Asset Management, L.P.
0.86%
Morgan Stanley & Co. LLC
0.28%
Greenleaf Trust
0.11%
UBS Financial Services, Inc.
0.08%
BNP Paribas Securities Corp. North America
0.06%
Other
98.60%
Aktionärstypen
Aktionäre
Anteil
Hedge Fund
0.86%
Research Firm
0.35%
Bank and Trust
0.11%
Investment Advisor
0.09%
Private Equity
0.04%
Other
98.56%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
25
222.41K
1.45%
+22.59K
2025Q1
25
242.89K
1.60%
+14.64K
2024Q4
25
125.35K
1.13%
-75.38K
2024Q3
25
113.89K
1.28%
-62.37K
2024Q2
24
79.19K
0.91%
-96.76K
2024Q1
24
95.17K
1.09%
-51.08K
2023Q4
23
88.25K
1.89%
-31.21K
2023Q3
26
59.08K
1.45%
-63.37K
2023Q2
27
58.44K
1.44%
-90.15K
2023Q1
26
93.79K
2.31%
-17.38K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Point72 Asset Management, L.P.
131.43K
0.86%
+98.80K
+302.83%
Mar 31, 2025
Morgan Stanley & Co. LLC
43.63K
0.29%
-700.00
-1.58%
Mar 31, 2025
UBS Financial Services, Inc.
13.00K
0.09%
+12.62K
+3286.46%
Mar 31, 2025
BNP Paribas Securities Corp. North America
9.75K
0.06%
+962.00
+10.94%
Mar 31, 2025
Twin Lakes Capital
5.92K
0.04%
--
--
Mar 31, 2025
Geode Capital Management, L.L.C.
1.16K
0.01%
--
--
May 31, 2025
Osaic Holdings, Inc.
181.00
0%
--
--
Mar 31, 2025
Rhumbline Advisers Ltd. Partnership
130.00
0%
+130.00
--
Mar 31, 2025
55IP
53.00
0%
+53.00
--
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Name
Anteil
Keine Daten
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Dec 30, 2022
Merger
10<1
Dec 30, 2022
Merger
10<1
Dec 30, 2022
Merger
10<1
Dec 30, 2022
Merger
10<1
Datum
Art
Verhältnis
Dec 30, 2022
Merger
10<1
Dec 30, 2022
Merger
10<1
Dec 30, 2022
Merger
10<1
Dec 30, 2022
Merger
10<1
